EUVIMEDEUVIMED entdecken
MetaanalyseSystematische ÜbersichtÜbersichtsarbeitOpen Access · CC BY-NC 4.0

Meta‐Analysis: High anti‐ HBs Titers are Associated with Significantly Reduced Risk of Hepatitis B Virus Reactivation During Rituximab Treatment

Shiva Poola, MaryKate Kratzer, Kerry Sewell iD, Zikun Yang, Hans L Tillmann

Alimentary Pharmacology & Therapeutics · 2026

DOI: 10.1111/apt.70490 ↗

Kurz gefasst

Metaanalyse in der Zeitschrift Alimentary Pharmacology & Therapeutics, 2026. Verfasst von Shiva Poola und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Division of Gastroenterology, Hepatology & Nutrition, Brody School of Medicine, East Carolina University/ECU Health Medical C…. Hauptthemen laut MEDLINE: Rituximab, Virus Activation, Hepatitis B Antibodies, Hepatitis B virus. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 47 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Hepatitis B virus (HBV) reactivation is a serious complication in patients receiving chronic immunosuppression. Anti‐CD20 agents such as Rituximab are considered high risk for HBV reactivation (> 10%); therefore, antiviral prophylaxis is recommended for all anti‐HBc positive patients. Some studies have suggested that patients with resolved HBV infection and higher hepatitis B surface antibody (anti‐HBs) titer have a higher level of protection against reactivation.

Aim

The purpose of this study was to systematically review the role of anti‐HBs titer on HBV reactivation in patients on rituximab while not on antiviral therapy/prophylaxis.

Methods

We systematically reviewed all studies that discussed HBV reactivation in patients on rituximab therapy with resolved HBV infection, defined as HBsAg negative and anti‐HBc positive, which discussed anti‐HBs titer. The search was conducted in PubMed, Embase via Elsevier, Scopus, and Cochrane CENTRAL inclusive July 2025. We evaluated the incidence of HBV reactivation from cohort studies that described anti‐HBs categorically based on anti‐HBs titer: ‘negative’ (titer < 10 iU/L), ‘10–100 iU/L’, or ‘> 100 iU/L’. Meta‐analysis statistics describe the proportion and risk difference for different anti‐HBs levels.

Results

The overall reactivation rate was 12.6%. There was a significant difference in HBV reactivation depending on titer: anti‐HBs negative 27.3% (51/195) (20.0%–36.0%), titer < 100 iU/L 13.8% (47/379) (8.8%–20.8%), and titer > 100 iU/L 3.5% (8/339) (1.8%–6.9%).

Conclusions

Those with anti‐HBs titer > 100 iU/L can be considered lower risk for HBV reactivation and may not require antiviral therapy, but monitoring with initiation of antiviral therapy if titer falls below 100 iU/L.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

RituximabVirus ActivationHepatitis B AntibodiesHepatitis B virusHepatitis BHumansHepatitis B Surface Antigens

Stichwörter der Autor:innen

anti‐HBs titerhepatitis B reactivationhepatitis B surface antibody titerreactivationrituximab

Substanzen

RituximabHepatitis B AntibodiesHepatitis B Surface Antigens

Autor:innen und Institutionen

  • Department of Medicine, Division of Gastroenterology, Hepatology & Nutrition, Brody School of Medicine, East Carolina University/ECU Health Medical Center, Greenville, North Carolina, USA.
  • Research Librarian for the Health Sciences, Brody School of Medicine, East Carolina University, Greenville, North Carolina, USA.
  • Department of Public Health, Brody School of Medicine, East Carolina University, Greenville, North Carolina, USA.

ORCID-Profile: Kerry Sewell

Zitieren

APA

Poola, S., Kratzer, M., Sewell, K., Yang, Z., & Tillmann, H. L. (2026). Meta‐Analysis: High anti‐ HBs Titers are Associated with Significantly Reduced Risk of Hepatitis B Virus Reactivation During Rituximab Treatment. Alimentary Pharmacology & Therapeutics. https://doi.org/10.1111/apt.70490

Vancouver

Poola S, Kratzer M, Sewell K, Yang Z, Tillmann HL. Meta‐Analysis: High anti‐ HBs Titers are Associated with Significantly Reduced Risk of Hepatitis B Virus Reactivation During Rituximab Treatment. Alimentary Pharmacology & Therapeutics. 2026. doi:10.1111/apt.70490

BibTeX
@article{Poola2026,
  author = {Poola, Shiva and Kratzer, MaryKate and Sewell, Kerry and Yang, Zikun and Tillmann, Hans L},
  title = {Meta‐Analysis: High anti‐ HBs Titers are Associated with Significantly Reduced Risk of Hepatitis B Virus Reactivation During Rituximab Treatment},
  journal = {Alimentary Pharmacology & Therapeutics},
  year = {2026},
  doi = {10.1111/apt.70490}
}
Kostenlos starten →